Evidence map›Paper›PMID 40760979›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Identifying dementia neuropathology using low-burden clinical data.

Yueqi Ren, Babak Shahbaba, Craig E L Stark

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Identifying dementia neuropathology using low-burden clinical data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yueqi RenMedical Scientist Training Program, School of Medicine, University of California Irvine, Irvine, California, USA.ORCID 0000-0003-2936-6009
Babak ShahbabaDepartment of Statistics, Donald Bren School of Information and Computer Sciences, University of California Irvine, Irvine, California, USA.
Craig E L StarkDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-9334-8502

Funding

National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BRADFORD C DICKERSON · 2019 to 2026
$36.5M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAMES B BREWER · 2019 to 2026
$34.9M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sanjay Asthana · 2019 to 2026
$34.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Pamela J McLean · 2019 to 2026
$33.5M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Margaret Sewell · 2020 to 2026
$31.0M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Caitlin Shannon Latimer · 2020 to 2026
$29.0M
National Alzheimer's Coordinating CenterNCI NIH HHS R01 CA297869NCI NIH HHS R01CA297869NIA-funded ADRCs P30 AG079280NIA NIH HHS F30AG079610NIA NIH HHS P20 AG068024NIA NIH HHS P20 AG068053NIA NIH HHS P20 AG068077NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS U24 AG072122NIH HHSNIMH NIH HHS R01MH115697
6 · The paper itself

Abstract

introductionIdentifying dementia neuropathology is critical for guiding effective therapies and clinical trials. To tackle this, we developed semi-supervised models for identifying neuropathology using low-burden data to improve generalizability.

methodsWe defined low-burden data as being reasonably obtainable at a primary care setting. By using a semi-supervised learning paradigm, we can amplify the utility of low-burden data. We trained a clustering and a semi-supervised prediction model to yield clustering and prediction results for different neuropathology lesion types.

resultsOur clustering model identified two clinically meaningful outlier groups that were either neuropathology-enriched or -scarce. We predicted neuropathology burden across different pathology types and found that using low-burden data over multiple clinical visits can predict neuropathology on par with using higher-burden data. DISCUSSION: This work fills a critical gap in the field by using low-burden clinical data to predict neuropathology, thereby improving dementia screening, therapy, and targeted clinical trials. HIGHLIGHTS: Clinical data are useful for neuropathology screening in future clinical trials. Novel application of semi-supervised learning for identifying neuropathology. Clustering model found groups with highly different neuropathology prevalence. Low-burden data can provide relatively accurate predictions of pathology load. Higher-burden, longitudinal data are most helpful for predicting vascular lesions.

Indexed as

BrainDementiaNeuropathologySupervised Machine LearningAgedAged, 80 and overCluster AnalysisFemaleHumansMaleAlzheimer's diseaseclusteringdiagnosis predictionmixed dementianeuropathology screeningprogression monitoringsemi‐supervised learningstatistical machine learning

Identifiers

PMID40760979
PMCPMC12322317

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.